Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen-receptor Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05607004
What this trial is testing

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Who this might be right for
Breast NeoplasmsInvasive Breast CancerEstrogen-receptor-positive Breast Cancer+1 more
Atossa Therapeutics, Inc. 87
Early research (Phase 1)Active Not RecruitingNCT05508906
What this trial is testing

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Who this might be right for
Metastatic Breast CancerER-positive Breast CancerHER2-negative Breast Cancer+2 more
Olema Pharmaceuticals, Inc. 190
Testing effectiveness (Phase 2)Looking for participantsNCT04886531
What this trial is testing

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Who this might be right for
Breast CancerHER2-positive Breast CancerER Positive Breast Cancer+1 more
Ruth O'Regan 30
Large-scale testing (Phase 3)Ended earlyNCT03050398
What this trial is testing

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 8
Not applicableEnded earlyNCT01155063
What this trial is testing

Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients

Who this might be right for
Early Breast Cancer
Pfizer 89
Testing effectiveness (Phase 2)Looking for participantsNCT06993844
What this trial is testing

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsAdvanced Breast Cancer
Ensem Therapeutics 233
Testing effectiveness (Phase 2)Looking for participantsNCT06150898
What this trial is testing

Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)

Who this might be right for
Early-stage Breast CancerEstrogen-receptor-positive Breast Cancer
Jules Bordet Institute 112
Large-scale testing (Phase 3)Study completedNCT00073528
What this trial is testing

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Novartis Pharmaceuticals 1,286
Early research (Phase 1)Ended earlyNCT05489679
What this trial is testing

AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 6
Testing effectiveness (Phase 2)Ended earlyNCT03289039
What this trial is testing

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 21
Testing effectiveness (Phase 2)Active Not RecruitingNCT06428396
What this trial is testing

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

Who this might be right for
Metastatic Breast Cancer
Merck Sharp & Dohme LLC 120
Testing effectiveness (Phase 2)Study completedNCT00003199
What this trial is testing

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerEstrogen Receptor-positive Breast CancerInflammatory Breast Cancer+5 more
Fred Hutchinson Cancer Center 50
Large-scale testing (Phase 3)Active Not RecruitingNCT06065748
What this trial is testing

Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Who this might be right for
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche 1,050
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07801898
What this trial is testing

Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer

Who this might be right for
Invasive Breast Cancer (Stage I-III)
The Second Hospital of Anhui Medical University 36
Not applicableUnknownNCT03790813
What this trial is testing

Informative Tools to Optimize Neoadjuvant Therapy in ER Positive, HER2 Negative Breast Cancers

Who this might be right for
Breast Cancer
British Columbia Cancer Agency 50
Not applicableNot Yet RecruitingNCT06623903
What this trial is testing

Early Changes in Metabolic Health in Breast Cancer Patients Initiating Endocrine Therapy

Who this might be right for
Early Breast CancerMetabolic HealthEstrogen Receptor Positive Breast Cancer
Aarhus University Hospital 112
Not applicableStudy completedNCT01928186
What this trial is testing

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeMale Breast Carcinoma+7 more
University of Washington 28
Not applicableEnrolling By InvitationNCT06629233
What this trial is testing

Evaluation of a Novel Technique for the Discovery of New, Tumor-specific Targets for the Deployment of Innovative Immunotherapeutics Against Cancer.

Who this might be right for
Estrogen Receptor Positive Breast Cancer
University Ghent 36
Not applicableLooking for participantsNCT04476485
What this trial is testing

Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy

Who this might be right for
Breast Cancer
Shengjing Hospital 1,000
Testing effectiveness (Phase 2)WithdrawnNCT01658176
What this trial is testing

Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
Pfizer
Next Page